Advertisement

Serum GDF15 Levels Correlate to Mitochondrial Disease Severity and Myocardial Strain, but Not to Disease Progression in Adult m.3243A>G Carriers

  • Saskia KoeneEmail author
  • Paul de Laat
  • Doorlène H. van Tienoven
  • Gert Weijers
  • Dennis Vriens
  • Fred C. G. J. Sweep
  • Janneke Timmermans
  • Livia Kapusta
  • Mirian C. H. Janssen
  • Jan A. M. Smeitink
Research Report
Part of the JIMD Reports book series (JIMD, volume 24)

Abstract

In this observational cohort study, we examined the prognostic value of growth and differentiation factor 15 (GDF15) in indicating and monitoring general mitochondrial disease severity and progression in adult carriers of the m.3243A>G mutation.

Ninety-seven adult carriers of the m.3243A>G mutation were included in this study. The Newcastle mitochondrial disease adult scale was used for rating mitochondrial disease severity. In parallel, blood was drawn for GDF15 analysis by ELISA. Forty-nine carriers were included in a follow-up study. In a small subset of subjects of whom an echocardiogram was available from general patient care, myocardial deformation was assessed using two-dimensional speckle-tracking strain analysis.

A moderate positive correlation was found between the concentration of GDF15 and disease severity (r = 0.59; p < 0.001). The concentration of serum GDF15 was higher in m.3243A>G carriers with diabetes mellitus, cardiomyopathy, and renal abnormalities. After a 2-year follow-up, no significant correlation was found between the change in disease severity and the change in the concentration of GDF15 or between the GDF15 level at the first assessment and the change in disease severity. In the subcohort of patients of whom an echocardiogram was available, the concentration of GDF15 correlated moderately to longitudinal global strain (r = 0.55; p = 0.006; n = 23) but not to circumferential or radial strain.

Our results indicate that serum GDF15 is not a strong surrogate marker for general mitochondrial disease severity. Its value in indicating myocardial deformation should be confirmed in a prospective longitudinal study.

Keywords

Mitochondrial Disease Global Longitudinal Strain Myocardial Strain Candidate Predictor Clinical Disease Severity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This work was partly supported by the Netherlands Organisation for Scientific Research (the NWO Centres for Systems Biology Research initiative), ZonMW (AGIKO grants Saskia Koene and Dennis Vriens), and Stichting Energy4All. We thank Inge Konijnenberg-Kramer for sample handling. Jan Smeitink is the CEO of Khondrion BV.

References

  1. Association WM (2013) Declaration of Helsinki – ethical principles for medical research involving human subjects. 64th WMA General Assembly, Fortaleza, BrazilGoogle Scholar
  2. Bates MG, Hollingsworth KG, Newman JH et al (2013) Concentric hypertrophic remodelling and subendocardial dysfunction in mitochondrial DNA point mutation carriers. Eur Heart J Cardiovasc Imaging 14:650–658PubMedCentralCrossRefPubMedGoogle Scholar
  3. Breit SN, Carrero JJ, Tsai VW et al (2012) Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. Nephrol Dial Transplant 27:70–75CrossRefPubMedGoogle Scholar
  4. Bulten BF, Mavinkurve-Groothuis AM, de Geus-Oei LF et al (2014) Early myocardial deformation abnormalities in breast cancer survivors. Breast Cancer Res Treat 146:127–135CrossRefPubMedGoogle Scholar
  5. de Laat P, Koene S, van den Heuvel LP, Rodenburg RJ, Janssen MC, Smeitink JA (2012) Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A>G mutation. J Inherit Metab Dis 11:1059–1969CrossRefGoogle Scholar
  6. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P (2014) Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol 2:01367–01368Google Scholar
  7. Emma F, Bertini E, Salviati L, Montini G (2012) Renal involvement in mitochondrial cytopathies. Pediatr Nephrol 27:539–550PubMedCentralCrossRefPubMedGoogle Scholar
  8. Hirano M, Konishi K, Arata N et al (2002) Renal complications in a patient with A-to-G mutation of mitochondrial DNA at the 3243 position of leucine tRNA. Intern Med 41:113–118CrossRefPubMedGoogle Scholar
  9. Ho JE, Mahajan A, Chen MH et al (2012) Clinical and genetic correlates of growth differentiation factor 15 in the community. Clin Chem 58:1582–1591PubMedCentralCrossRefPubMedGoogle Scholar
  10. Ho JE, Hwang SJ, Wollert KC et al (2013) Biomarkers of cardiovascular stress and incident chronic kidney disease. Clin Chem 59:1613–1620PubMedCentralCrossRefPubMedGoogle Scholar
  11. Hollingsworth KG, Gorman GS, Trenell MI et al (2012) Cardiomyopathy is common in patients with the mitochondrial DNA m.3243A>G mutation and correlates with mutation load. Neuromuscul Disord 22:592–596CrossRefPubMedGoogle Scholar
  12. Izumiya Y, Hanatani S, Kimura Y et al (2014) Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. Can J Cardiol 30:338–344CrossRefPubMedGoogle Scholar
  13. Kalko SG, Paco S, Jou C et al (2014) Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies. BMC Genomics 15:91PubMedCentralCrossRefPubMedGoogle Scholar
  14. Kempf T, Wollert KC (2013) Risk stratification in critically ill patients: GDF-15 scores in adult respiratory distress syndrome. Crit Care 17:173PubMedCentralCrossRefPubMedGoogle Scholar
  15. Koene S, de Laat P, van Tienoven DH et al (2014) Serum FGF21 levels in adult m.3243A>G carriers: clinical implications. Neurology 6:125–133CrossRefGoogle Scholar
  16. Lee SK, Kim J, Kim HD, Lee JS, Lee YM (2010) Initial experiences with proton MR spectroscopy in treatment monitoring of mitochondrial encephalopathy. Yonsei Med J 51:672–675PubMedCentralCrossRefPubMedGoogle Scholar
  17. Lok SI, Winkens B, Goldschmeding R et al (2012) Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail 14:1249–1256CrossRefPubMedGoogle Scholar
  18. Mayeux R (2004) Biomarkers: potential uses and limitations. NeuroRx 1:182–188PubMedCentralCrossRefPubMedGoogle Scholar
  19. Montoro-Garcia S, Hernandez-Romero D, Jover E et al (2012) Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy. Eur J Intern Med 23:169–174CrossRefPubMedGoogle Scholar
  20. Moore AG, Brown DA, Fairlie WD et al (2000) The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. J Clin Endocrinol Metab 85:4781–4788PubMedGoogle Scholar
  21. Pfeffer G, Horvath R, Klopstock T et al (2013) New treatments for mitochondrial disease-no time to drop our standards. Nat Rev Neurol 9:474–481CrossRefPubMedGoogle Scholar
  22. Plana JC, Galderisi M, Barac A et al (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 15:1063–1093CrossRefPubMedGoogle Scholar
  23. Schaefer AM, Phoenix C, Elson JL, McFarland R, Chinnery PF, Turnbull DM (2006) Mitochondrial disease in adults: a scale to monitor progression and treatment. Neurology 66:1932–1934CrossRefPubMedGoogle Scholar
  24. St John Sutton M, Ky B, Regner SR et al (2014) Longitudinal strain in Friedreich Ataxia: a potential marker for early left ventricular dysfunction. Echocardiography 31:50–57CrossRefPubMedGoogle Scholar
  25. Suomalainen A (2011) Biomarkers for mitochondrial respiratory chain disorders. J Inherit Metab Dis 34:277–282CrossRefPubMedGoogle Scholar
  26. Trovik J, Salvesen HB, Cuppens T, Amant F, Staff AC (2014) Growth differentiation factor-15 as biomarker in uterine sarcomas. Int J Gynecol Cancer 24:252–259CrossRefPubMedGoogle Scholar
  27. Xu X, Li Z, Gao W (2011) Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside. Biomarkers 16:466–475CrossRefPubMedGoogle Scholar
  28. Yang CZ, Ma J, Zhu DW et al (2014) GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma. Ann Oncol 24:24Google Scholar
  29. Yatsuga S, Koga Y (2014) Growth differentiation factor 15 and fibroblast growth factor 21: novel biomarkers for mitochondrial diseases United Mitochondrial Disease Foundation Conference 2014Google Scholar

Copyright information

© SSIEM and Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Saskia Koene
    • 1
    Email author
  • Paul de Laat
    • 1
  • Doorlène H. van Tienoven
    • 2
  • Gert Weijers
    • 3
  • Dennis Vriens
    • 3
  • Fred C. G. J. Sweep
    • 2
  • Janneke Timmermans
    • 4
  • Livia Kapusta
    • 5
    • 6
  • Mirian C. H. Janssen
    • 1
    • 7
  • Jan A. M. Smeitink
    • 1
  1. 1.Department of PediatricsNijmegen Centre for Mitochondrial Disorders, Amalia Children’s Hospital, RadboudumcNijmegenThe Netherlands
  2. 2.Department of Laboratory MedicineRadboudumcNijmegenThe Netherlands
  3. 3.Department of Radiology and Nuclear MedicineRadboudumcNijmegenThe Netherlands
  4. 4.Department of CardiologyRadboudumcNijmegenThe Netherlands
  5. 5.Department of Pediatric CardiologyAmalia Children’s Hospital, RadboudumcNijmegenThe Netherlands
  6. 6.Department of Pediatrics, Pediatric Cardiology UnitTel-Aviv Sourasky Medical CenterTel AvivIsrael
  7. 7.Department of General Internal MedicineRadboudumcNijmegenThe Netherlands

Personalised recommendations